Clinical trial • Phase IV • Musculoskeletal|Other

CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS for Temporomandibular disorder

Phase IV trial of CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS for Temporomandibular disorder. 1 participants.

Overview

Trial Therapeutic Area
Musculoskeletal|Other
Trial Disease
Temporomandibular disorder
Trial Stage
Phase IV
Drug Modality
Peptide/protein/enzyme

Key dates

Initial CTIS Submission Date
26-10-2023
First CTIS Authorization Date
05-02-2024

Trial design

Phase IV trial in Sweden.

Target Sample Size
1

Eligibility

Recruits 1 No vulnerable populations selected. Only adults aged 18-45 are eligible. No assent/consent handling details are provided. Exclusion includes "difficulties understanding the Swedish language.".

Pregnancy Exclusion
9) pregnancy or nursing
Vulnerable Population
No vulnerable populations selected. Only adults aged 18-45 are eligible. No assent/consent handling details are provided. Exclusion includes "difficulties understanding the Swedish language."

Inclusion criteria

  • {"criterion_text":"- a) Female gender\n- b) age 18-45 years\n- c) diagnos of myalgia, myofacial pain or myofascial pain with refered pain according to DC/TMD\n- d) an average pain due to NRS ≥ 3 for more than three months\n- e) treatment for orofacial pain > three months ago.\n- f) with adequate contraceptives and a negative pregnancy test. Patients will still be included even if they have one or more co-diagnoses 1) Discdisplacement with or without reduction according to DC/TMD 2) degenerative joint disease 3) arthralgia"}

Exclusion criteria

  • {"criterion_text":"- 1) treatment with BTX during the last six months\n- 2) treatment for orofacial pain within the last 3 months.\n- 3) systemic inflammatory diseases (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis)\n- 4) fibromyalgia\n- 5) neuropathic pain\n- 6) neurologic disease (myastenia gravis)\n- 7) pain of dental origin\n- 8) use of muscle relaxants or aminoglycoside antibiotics\n- 9) pregnancy or nursing\n- 10) hypersensitivity to BTX\n- 11) neuropsychiatric conditions.\n- 12) difficulties understanding the Swedish language.\n- 13) Trauma to head, neck or face, including orthognatic surgery"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Changes in pain and if the dose matters for pain relief is the primary outcome.","definition_or_measurement_approach":""}

Secondary endpoints

  • {"endpoint_text":"- Changes in quality of life according to OHIP. Treatment outcome in sub-groups of myogenous TMD. Maximum jaw opening with and without pain between doses and subgroups. The patient´s changes psychosocially, how the jawfunction is affected according to changes in Axis II and changes in PPT.","definition_or_measurement_approach":""}

Recruitment

Planned Sample Size
1
Recruitment Window Months
23

Geography

Total Number Of Sites
1
Total Number Of Participants
1

Sweden

Earliest CTIS Part Ii Submission Date
17-01-2024
Latest Decision Or Authorization Date
05-02-2024
Processing Time Days
19
Number Of Sites
1
Number Of Participants
1

Sites

Site Name
Region Stockholm Folktandvarden
Department Name
Avdelningen för bettfysiologi
Contact Person Name
Veronica de Flon
Number Of Participants
1

Sponsor

Primary sponsor

Full Name
Region Stockholm Folktandvarden
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Sweden

Investigational products

Investigational Product Name
CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS
Active Substance
CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS
Modality
Peptide/protein/enzyme
Routes Of Administration
DENTAL USE
Route
DENTAL USE
Maximum Dose
100 U unit(s)

Related trials

Other published trials that may interest you.